Drug-Induced thrombocytopenia

Platelets

Volumn , Issue , 2007, Pages 887-902

  Aster, Richard H ^a,b  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547806285     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50811-9     Document Type: Chapter

References (179)

1. Garratty G. Immune cytopenia associated with antibiotics. Transf Med Rev 1993, 7:255-267.
2. Pedersen-Bjergaard U., Andersen M., Hansen P.B. Drug-induced thrombocytopenia: Clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 1997, 52:183-189.
3. Pedersen-Bjergaard U., Andersen M., Hansen P.B. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998, 54:701-706.
4. George J.N., Raskob G.E., Shah S.R., et al. Druginduced thrombocytopenia: A systematic review of published case reports. Ann Intern Med 1998, 129:886-890.
5. Aster R. Response of thrombocytes to toxic injury. Comprehensive toxicology 1997, Vol. IV:263-268. Elsevier Science. I.G. Sipes, A.J. Gandolfi, C.A. McQueen (Eds.).
6. Wazny L.D., Ariano R.E. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000, 20:292-307.
7. Aster R.H. Drug-induced immune cytopenias. Toxicology 2005, 209:149-153.
8. Carey P.J. Drug-induced myelosuppression: Diagnosis and management. Drug Saf 2003, 26:691-706.
9. Blay J.Y., Le Cesne A., Mermet C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 1998, 92:405-410.
10. Recombinant interleukin-11 for chemotherapy-induced thrombocytopenia. Med Lett Drugs Ther 1998, 40:77-78.
11. Cantor S.B., Elting L.S., Hudson D.V., et al. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 2003, 97:3099-3106.
12. Vadhan-Raj S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol 2000, 37:28-34.
13. Vadhan-Raj S., Patel S., Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 2003, 21:3158-3167.
14. Stone R.M., Berg D.T., George S.L., et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995, 332:1671-1677.
15. Michel G., Landman-Parker J., Auclerc M.F., et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: A randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 2000, 18:1517-1524.
16. Newland A.C. Is interleukin 3 active in anticancer drug-induced thrombocytopenia?. Cancer Chemother Pharmacol 1996, 38:S83-S88. Suppl.
17. Phillips K.A., Tannock I.F. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998, 16:3179-3190.
18. Budd G.T., Ganapathi R., Wood L., et al. Approaches to managing carboplatin-induced thrombocytopenia: Focus on the role of amifostine. Semin Oncol 1999, 26:41-50.
19. Koch M.A., Volberding P.A., Lagakos S.W., et al. Toxic effects of zidovudine in asymptomatic human immu-nodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10 (9) /L or less: Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group. Arch Intern Med 1992, 152:2286-2292.
20. Kaufman D.W., Kelly J.P., Jurgelon J.M., et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 1996, 60:23-30.
21. Young N.S. Immune pathophysiology of acquired aplastic anaemia. Eur J Haematol Suppl 1996, 60:55-59.
22. Wiholm B.E., Emanuelsson S. Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. Eur J Haematol Suppl 1996, 60:42-46.
23. Dingli D., Tefferi A. A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leuk Lymphoma 2005, 46:641-650.
24. Wang G., Franklin R., Hong Y, et al. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol 2005, 146:324-332.
25. Silverstein M.N., Tefferi A. Treatment of essential thrombocythemia with anagrelide. Semin Hematol 1999, 36:23-25.
26. McCune J.S., Liles D., Lindley C. Precipitous fall in platelet count with anagrelide: Case report and critique of dosing recommendations. Pharmacotherapy 1997, 17:822-826.
27. Girard D.E., Kumar K.L., McAfee J.H. Hematologic effects of acute and chronic alcohol abuse. Hematol Oncol Clin North Am 1987, 1:321-334.
28. Gewirtz A.M., Hoffman R. Transitory hypomegakaryocytic thrombocytopenia: Aetiological association with ethanol abuse and implications regarding regulation of human megakaryocytopoiesis. Br J Haematol 1986, 62:333-344.
29. Mikhailidis D.P., Barradas M.A., Jeremy J.Y. The effect of ethanol on platelet function and vascular prostanoids. Alcohol 1990, 7:171-180.
30. Aranda E., Pizarro M., Pereira J, et al. Accumulation of 5-hydroxytryptamine by aging platelets: Studies in a model of suppressed thrombopoiesis in dogs. Thromb Haemost 1994, 71:488-492.
31. Cooper B.A., Bigelow F.S. Thrombocytopenia associated with the administration of diethylstilbestrol in man. Ann Intern Med 1960, 52:907-909.
32. Onel K., Bussel J.B. Adverse effects of estrogen therapy in a subset of women with ITP. J Thromb Haemost 2004, 2:670-671.
33. Rakela J., Wood J.R., Czaja A.J., et al. Long-term versus short-term treatment with recombinant interferon alfa-2a in patients with chronic hepatitis B: A prospective, randomized treatment trial. Mayo Clin Proc 1990, 65:1330-1335.
34. Martin T.G., Shuman M.A. Interferon-induced thrombocytopenia: Is it time for thrombopoietin?. Hepatology 1998, 28:1430-1432.
35. Toccaceli F., Rosati S., Scuderi M, et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepato gastroenterology 1998, 45:1748-1752.
36. Ganser A., Carlo-Stella C., Greher J, et al. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987, 70:1173-1179.
37. Sevastianos V.A., Deutsch M., Dourakis S.P., et al. Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C. Am J Gastroenterol 2003, 98:706-707.
38. Fujii H., Kitada T., Yamada T, et al. Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C. Hepatogastroenterology 2003, 50:841-842.
39. Sata M., Yano Y., Yoshiyama Y, et al. Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B. J Gastroenterol 1997, 32:206-210.
40. Trannel T.J., Ahmed I., Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry 2001, 158:128-130.
41. Kaufman K.R., Gerner R. Dose-dependent valproic acid thrombocytopenia in bipolar disorder. Ann Clin Psychiatry 1998, 10:35-37.
42. Eastham R.D., Jancar J. Sodium valproate and platelet counts. Br Med J 1980, 280:186.
43. May R.B., Sunder T.R. Hematologic manifestations of long-term valproate therapy. Epilepsia 1993, 34:1098-1101.
44. Brichard B., Vermylen C., Scheiff J.M, et al. Haematological disturbances during long-term valproate therapy. Eur J Pediatr 1994, 153:378-380.
45. Gesundheit B., Kirby M., Lau W, et al. Thrombocytopenia and megakaryocyte dysplasia: An adverse effect of valproic acid treatment. J Pediatr Hematol Oncol 2002, 24:589-590.
46. Proulle V., Masnou P., Cartron J, et al. GPIaIIa as a candidate target for anti-platelet autoantibody occurring during valproate therapy and associated with preoperative bleeding. Thromb Haemost 2000, 83:175-176.
47. Sleiman C., Raffy O., Roue C, et al. Fatal pulmonary hemorrhage during high-dose valproate monotherapy. Chest 2000, 117:613.
48. Miyazawa K., Nishimaki J., Katagiri T, et al. Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: Is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?. Int J Hematol 2003, 77:93-95.
49. Ault P., Kantarjian H., Welch M.A, et al. Interleukin 11 may improve thrombocytopenia associated with imatinib mesylate therapy in chronic myelogenous leukemia. Leuk Res 2004, 28:613-618.
50. Marin D., Marktel S., Foot N, et al. Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 2003, 88:227-229.
51. Attassi K., Hershberger E., Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002, 34:695-698.
52. Orrick J.J., Johns T., Janelle J., et al. Thrombocytopenia secondary to linezolid administration: What is the risk?. Clin Infect Dis 2002, 35:348-349.
53. Gerson S.L., Kaplan S.L., Bruss J.B., et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 2005, 46:2723-2726.
54. Mannucci P.M. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997, 90:2515-2521.
55. Casonato A., Pontara E., Dannhaeuser D, et al. Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease. Blood Coagul Fibrinolysis 1994, 5:959-964.
56. Takahashi H., Okada K., Abe S, et al. Platelet aggregation induced by cryoprecipitate infusion in platelet-type von Willebrand's disease. Thromb Res 1987, 46:255-262.
57. Stratton J., Warwicker P., Watkins S, et al. Desmopressin may be hazardous in thrombotic microangiopathy. Nephrol Dial Transplant 2001, 16:161-162.
58. Overman M., Brass E. Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration. Thromb Haemost 2004, 92:886-887.
59. Bukowski R.M., Murthy S., McLain D., et al. Phase I trial of recombinant granulocyte-macrophage colonystimulating factor in patients with lung cancer: Clinical and immunologic effects. J Immunother 1993, 13:267-274.
60. Tortajada C., Garcia F., Miro J.M., et al. Severe thrombocytopenia related to granulocyte-macrophage colonystimulating factor (rHU-GM-CSF). An Med Interna 2000, 17:671.
61. Nash R.A., Burstein S.A., Storb R., et al. Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: Increased destruction of circulating platelets. Blood 1995, 86:1765-1775.
62. Abramsm K., Yunusov M.Y., Slichter S., et al. Recombinant human macrophage colony-stimulating factorinduced thrombocytopenia in dogs. Br J Haematol 2003, 121:614-622.
63. Baker G.R., Levin J. Transient thrombocytopenia produced by administration of macrophage colonystimulating factor: Investigations of the mechanism. Blood 1998, 91:89-99.
64. Michelmann I., Bockmann D., Nurnberger W, et al. Thrombocytopenia and complement activation under recombinant TNF alpha/IFN gamma therapy in man. Ann Hematol 1997, 74:179-184.
65. Paciucci P.A., Mandeli J., Oleksowicz L., et al. Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion. Am J Med 1990, 89:308-312.
66. Fleischmann J.D., Shingleton W.B., Gallagher C., et al. Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy. J Lab Clin Med 1991, 117:76-82.
67. Gringeri A., Santagostino E., Tradati F, et al. Adverse effects of treatment with porcine factor VIII. Thromb Haemost 1991, 65:245-247.
68. Chang H., Mody M., Lazarus A.H., et al. Platelet activation induced by porcine factor VIII (Hyate:C). Am J Hematol 1998, 57:200-205.
69. Wakefield T.W., Bouffard J.A., Spaulding S.A., et al. Sequestration of platelets in the pulmonary circulation as a consequence of protamine reversal of the anticoagulant effects of heparin. J Vasc Surg 1987, 5:187-193.
70. Al-Mondhiry H., Pierce W.S., Basarab R.M. Protamine-induced thrombocytopenia and leukopenia. Thromb Haemost 1985, 53:60-64.
71. Kinney E.L., Ballard J.O., Carlin B., et al. Amrinone-mediated thrombocytopenia. Scand J Haematol 1983, 31:376-380.
72. Ross M.P., Allen-Webb E.M., Pappas J.B., et al. Amrinone-associated thrombocytopenia: Pharmacokinetic analysis. Clin Pharmacol Ther 1993, 53:661-667.
73. Garratty G., Petz L.D. Drug-induced immune hemolytic anemia. Am J Med 1975, 58:398-407.
74. Murphy M.F., Riordan T., Minchinton R.M., et al. Demonstration of an immune-mediated mechanism of penicillin-induced neutropenia and thrombocytopenia. Br J Haematol 1983, 55:155-160.
75. Lang R., Lishner M., Ravid M. Adverse reactions to prolonged treatment with high doses of carbenicillin and ureidopenicillins. Rev Infect Dis 1991, 13:68-72.
76. Parker J.C., Barrett D.A. Microangiopathic hemolysis and thrombocytopenia related to penicillin drugs. Arch Intern Med 1971, 127:474-477.
77. Christie D.J., Lennon S.S., Drew R.L., et al. Cefotetan-induced immunologic thrombocytopenia. Br J Haematol 1998, 70:423-426.
78. Shulman N.R., Reid D.M. Mechanisms of druginduced immunologically mediated cytopenias. Transfus Med Rev 1993, 7:215-229.
79. Aster R.H. Drug-induced immune thrombocytopenia: An overview of pathogenesis. Semin Hematol 1999, 36:2-6.
80. Christie D.J., Aster R.H. Drug-antibody-platelet interaction in quinine-and quinidine-induced thrombocytopenia. J Clin Invest 1982, 70:989-998.
81. Christie D.J., Mullen P.C., Aster R.H. Fabmediated binding of drug-dependent antibodies to platelets in quinidine-and quinine-induced thrombocytopenia. J Clin Invest 1985, 75:310-314.
82. Smith M.E., Reid D.M., Jones C.E., et al. Binding of quinine-and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest 1987, 79:912-917.
83. Chong B.H., Du X.P., Berndt M.C., et al. Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidinedependent antibodies. Blood 1991, 77:2190-2199.
84. Visentin G.P., Newman P.J., Aster R.H. Characteristics of quinine-and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 1991, 77:2668-2676.
85. Lopez J.A., Li C.Q., Weisman S., et al. The glycoprotein Ib-IX complex-specific monoclonal antibody SZ1 binds to a conformation-sensitive epitope on glycoprotein IX: Implications for the target antigen of quinine/quinidinedependent autoantibodies. Blood 1995, 85:1254-1258.
86. Curtis B.R., McFarland J.G., Wu G.G., et al. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994, 176-183.
87. Gentilini G., Curtis B.R., Aster R.H. An antibody from a patient with ranitidine-induced throm bocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood 1998, 92:2359-2365.
88. Pereira J., Hidalgo P., Ocqueteau M, et al. Glycoprotein Ib/IX complex is the target in rifampicininduced immune thrombocytopenia. Br J Haematol 2000, 110:907-910.
89. Asvadi P., Ahmadi Z., Chong B.H. Druginduced thrombocytopenia: Localization of the binding site of GPIX-specific quinine-dependent antibodies. Blood 2003, 102:1670-1677.
90. Grossjohann B., Eichler P., Greinacher A, et al. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: Characterization of targets on platelets and red blood cells. Transfusion 2004, 44:1033-1040.
91. Garner S.F., Campbell K., Smith G., et al. Teicoplanin-dependent antibodies: Detection and characterization. Br J Haematol 2005, 129:279-281.
92. Kroll H., Sun Q.H., Santoso S. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia. Blood 2000, 96:1409-1414.
93. Burgess J.K., Lopez J.A., Gaudry L.E., et al. Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies. Blood 2000, 95:1988-1992.
94. Burgess J.K., Lopez J.A., Berndt M.C., et al. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: Characterization of the epitopes. Blood 1998, 92:2366-2373.
95. Peterson J.A., Nyree C.E., Newman P.J., et al. A site involving the "hybrid" and PSI homology domains of GPIIIa (beta 3-integrin subunit) is a common target for antibodies associated with quinine-induced immune thrombocytopenia. Blood 2003, 101:937-942.
96. Worlledge S.M. Immune drug-induced hemolytic anemias. Semin Hematol 1973, 10:327-344.
97. Petz L.D. Drug-induced autoimmune hemolytic anemia. Transfus Med Rev 1993, 7:242-254.
98. Adachi J.D., Bensen W.G., Kassam Y., et al. Gold induced thrombocytopenia: twelve cases and a review of the literature. Semin Arthritis Rheum 1987, 16:287-293.
99. von dem Borne A.E., Pegels J.G., van der Stadt R.J., et al. Thrombocytopenia associated with gold therapy: A drug-induced autoimmune disease?. Br J Haematol 1986, 63:509-516.
100. Levin M.D., van T Veer M.B., de Veld J.C., et al. Two patients with acute thrombocytopenia following gold administration and five-year follow-up. Neth J Med 2003, 61:223-225.
101. Garner S.F., Campbell K., Metcalfe P., et al. Glycoprotein V: The predominant target antigen in gold-induced autoimmune thrombocytopenia. Blood 2002, 100:344-346.
102. Aster R.H. Can drugs cause autoimmune thrombocytopenic purpura?. Semin Hematol 2000, 37:229-238.
103. Landrum E.M., Siegert E.A., Hanlon J.T., et al. Prolonged thrombocytopenia associated with procainamide in an elderly patient. Ann Pharmacother 1994, 28:1172-1176.
104. Giner V., Rueda D., Salvador A, et al. Thrombocytopenia associated with levodopa treatment. Arch Intern Med 2003, 163:735-736.
105. Lerner W., Caruso R., Faig D, et al. Drug-dependent and non-drug-dependent antiplatelet anti-body in druginduced immunologic thrombocytopenic purpura. Blood 1985, 66:306-311.
106. Griem P., Gleichmann E. Metal ion induced autoimmunity. Curr Opin Immunol 1995, 7:831-838.
107. Topol E.J., Byzova T.V., Plow E.F. Platelet GPIIb-IIIa blockers. Lancet 1999, 353:227-231.
108. Aster R.H. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005, 127:53S-59S.
109. Bougie D.W., Wilker P.R., Wuitschick E.D., et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligandoccupied GPIIb/IIIa. Blood 2002, 100:2071-2076.
110. Rezkalla S.H., Hayes J.J., Curtis B.R., et al. Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovasc Interv 2003, 58:76-79.
111. Morel O., Jesel L., Chauvin M, et al. Eptifibatideinduced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome. J Thromb Haemost 2003, 1:2685-2687.
112. Coons J.C., Barcelona R.A., Freedy T., et al. Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother 2005, 39:368-372.
113. Brassard J.A., Curtis B.R., Cooper R.A., et al. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: Evidence for an immune etiology. Thromb Haemost 2002, 88:892-897.
114. Seiffert D., Stern A.M., Ebling W., et al. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: Implications for the etiology of thrombocytopenia. Blood 2003, 101:58-63.
115. Frelinger A.L., Du X.P., Plow E.F, et al. Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem 1991, 266:17106-17111.
116. Jennings L.K., White M.M. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors. Am Heart J 1998, 135:S179-S183.
117. Madan M., Berkowitz S.D. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J 1999, 138:317-326.
118. Cines D.B. Glycoprotein IIb/IIIa antagonists: Potential induction and detection of drug-dependent antiplatelet antibodies. Am Heart J 1998, 135:S152-S159.
119. Coller B.S. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997, 78:730-735.
120. Artoni A., Li J., Mitchell B, et al. Integrin beta3 regions controlling binding of murine mAb 7E3: Implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci USA 2004, 101:13114-13120.
121. Berkowitz S.D., Sane D.C., Sigmon K.N., et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization: Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998, 32:311-319.
122. Jubelirer S.J., Koenig B.A., Bates M.C. Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: Case reports, review of the literature and implications for therapy. Am J Hematol 1999, 61:205-208.
123. Dery J.P., Braden G.A., Lincoff A.M., et al. Final results of the ReoPro readministration registry. Am J Cardiol 2004, 93:979-984.
124. Curtis B.R., Swyers J., Divgi A., et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002, 99:2054-2059.
125. Lown J.A., Hughes A.S., Cannell P. Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies. Heart 2004, 90:e55.
126. Moshiri S., Di Mario C., Liistro F, et al. Severe intracranial hemorrhage after emergency carotid stenting and abciximab administration for postoperative thrombosis. Catheter Cardiovasc Interv 2001, 53:225-228.
127. Mascelli M.A., Lance E.T., Damaraju L., et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998, 97:1680-1688.
128. Curtis B.R., Divgi A., Garritty M., et al. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004, 2:985-992.
129. Christopoulosm C.G., Machin S.J. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody. Br J Haematol 1994, 87:650-652.
130. Sane D.C., Damaraju L.V., Topol E.J., et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000, 36:75-83.
131. George J., Rizva M. Thrombocytopenia. Williams hematology 2005, 1479-1494. McGraw Hill, New York. 6th ed. E. Beutler, M. Lichtman, B. Coller, T. Kipps, U. Seligsohn (Eds.).
132. Hibbard A.B., Medina P.J., Vesely S.K. Reports of drug-induced thrombocytopenia. Ann Intern Med 2003, 138:239.
133. Rizvi M.A., Kojouri K., George J.N. Druginduced thrombocytopenia: An updated systematic review. Ann Intern Med 2001, 134:346.
134. Majhail N.S., Lichtin A.E. What is the best way to determine if thrombocytopenia in a patient on multiple medications is drug-induced?. Cleve Clin J Med 2002, 69:259-262.
135. Li X., Hunt L., Vesely S.K. Drug-induced thrombocytopenia: An updated systematic review. Ann Intern Med 2005, 142:474-475.
136. Tisdale J.F., Figg W.D., Reed E., et al. Severe thrombocytopenia in patients treated with suramin: Evidence for an immune mechanism in one. Am J Hematol 1996, 51:152-157.
137. Bozec L., Bierling P., Fromont P, et al. Irinotecaninduced immune thrombocytopenia. Ann Oncol 1998, 9:453-455.
138. Fernandez M.J., Llopis I., Pastor E., et al. Immune thrombocytopenia induced by fludarabine successfully treated with rituximab. Haematologica 2003, 88:ELT02.
139. Khatua S., Nair C.N., Ghosh K. Immunemediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: The unresolved issues. J Pediatr Hematol Oncol 2004, 26:777-779.
140. Pamuk G.E., Donmez S., Turgut B., et al. Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol 2005, 78:81.
141. Curtis B.R.(in press), Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol.
142. Salama A., Mueller-Eckhardt C., Kissel K, et al. Ex vivo antigen preparation for the serological detection of drug-dependent antibodies in immune haemolytic anaemias. Br J Haematol 1984, 58:525-531.
143. Salama A., Gottsche B., Mueller-Eckhardt C. Autoantibodies and drug-or metabolite-dependent antibodies in patients with diclofenac-induced immune haemolysis. Br J Haematol 1991, 77:546-549.
144. Bougie D., Johnson S.T., Weitekamp L.A., et al. Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Blood 1997, 90:407-413.
145. Cunha P.D., Lord R.S., Johnson S.T., et al. Immune hemolytic anemia caused by sensitivity to a metabolite of etodolac, a nonsteroidal anti-inflammatory drug. Transfusion 2000, 40:663-668.
146. Mueller-Eckhardt C., Salama A. Drug-induced immune cytopenias: A unifying pathogenetic concept with special emphasis on the role of drug metabolites. Transfus Med Rev 1990, 4:69-77.
147. Eisner E.V., Shahidi N.T. Immune thrombocytopenia due to a drug metabolite. N Engl J Med 1992, 287:376-381.
148. Bougie D., Aster R. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood 2001, 97:3846-3850.
149. Eisner E.V., Kasper K. Immune thrombocytopenia due to a metabolite of para-aminosalicylic acid. Am J Med 1972, 53:790-796.
150. Kiefel V., Santoso S., Schmidt S, et al. Metabolitespecifi c (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprim-sulfamethoxazole-induced immune thrombocytopenia. Transfusion 1987, 27:262-265.
151. Meyer T., Herrmann C., Wiegand V, et al. Immune thrombocytopenia associated with hemorrhagic diathesis due to ibuprofen administration. Clin Invest 1993, 71:413-415.
152. Meyer O., Hoffmann T., Aslan T, et al. Diclofenacinduced antibodies against RBCs and platelets: Two case reports and a concise review. Transfusion 2003, 43:345-349.
153. Kojouri K., Perdue J.J., Medina P.J., et al. Occult quinine-induced thrombocytopenia. J Okla State Med Assoc 2000, 93:519-521.
154. Reddy J.C., Shuman M.A., Aster R.H. Quinine/ quinidine-induced thrombocytopenia: A great imitator. Arch Intern Med 2004, 164:218-220.
155. Belkin G.A. Cocktail purpura: An unusual case of quinine sensitivity. Ann Intern Med 1967, 66:583-586.
156. Siroty R.R. Purpura on the rocks -with a twist. JAMA 1976, 235:2521-2522.
157. Reid D.M., Shulman N.R. Drug purpura due to surreptitious quinidine intake. Ann Intern Med 1988, 108:206-208.
158. Abraham R., Whitehead S. Factitious quinineinduced thrombocytopenia. Med J Aust 1998, 168:19-20.
159. Christie D.J., Walker R.H., Kolins M.D., et al. Quinine-induced thrombocytopenia following intravenous use of heroin. Arch Intern Med 1983, 143:1174-1175.
160. Khaleeli A.A. Quinaband-induced thrombocytopenic purpura in a patient with myxoedema coma. Br Med J 1976, 2:562-563.
161. Maloley P.A., Nelson E., Montgomery H.A., et al. Severe reversible thrombocytopenia resulting from butoconazole cream. Dicp 1990, 24:143-144.
162. Zeigler Z., Shadduck R.K., Winkelstein A., et al. Immune hemolytic anemia and thrombocytopenia secondary to quinidine: In vitro studies of the quinidine-dependent red cell and platelet antibodies. Blood 1979, 53:396-402.
163. Stroncek D.F., Vercellotti G.M., Hammerschmidt D.E., et al. Characterization of multiple quininedependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood 1992, 80:241-248.
164. Gottschall J.L., Elliot W., Lianos E., et al. Quinineinduced immune thrombocytopenia associated with hemolytic uremic syndrome: A new clinical entity. Blood 1991, 77:306-310.
165. Kojouri K., Vesely S.K., George J.N. Quinineassociated thrombotic thrombocytopenic purpurahemolytic uremic syndrome: Frequency, clinical features, and longterm outcomes. Ann Intern Med 2001, 135:1047-1051.
166. Wolf B., Conradty M., Grohmann R, et al. A case of immune complex hemolytic anemia, thrombocytopenia, and acute renal failure associated with doxepin use. J Clin Psychiatry 1989, 50:99-100.
167. Juang Y.C., Tsao T.C., Chiang Y.C., et al. Acute renal failure and severe thrombocytopenia induced by rifampicin: Report of a case. J Formos Med Assoc 1992, 91:475-476.
168. Coates A.S., Childs A., Cox K., et al. Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. Ann Oncol 1992, 3:719-722.
169. Dlott J.S., Danielson C.F., Blue-Hnidy D.E., et al. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: A concise review. Ther Apher Dial 2004, 8:102-111.
170. Visentin G.P., Wolfmeyer K., Newman P.J., et al. Detection of drug-dependent, platelet-reactive antibodies by antigen-capture ELISA and flow cytometry. Transfusion 1990, 30:694-700.
171. McFarland J.G. Laboratory investigation of druginduced immune thrombocytopenias. Transfus Med Rev 1993, 7:275-287.
172. Shulman N.R. Immunoreactions involving platelets. IV. Studies on the pathogenesis of thrombocytopenia in drug purpura using test doses of quinidine in sensitized individuals; their implications in idiopathic thrombocytopenic purpura. J Exp Med 1958, 107:711-729.
173. Glass J.T., Williams J.P., Mankad V.N., et al. Intracranial hemorrhage associated with quinidine induced thrombocytopenia. Ala Med 1989, 59:21-25.
174. Freiman J.P. Fatal quinine-induced thrombocytopenia. Ann Intern Med 1990, 112:308-309.
175. Fireman Z., Yust I., Abramov A.L. Lethal occult pulmonary hemorrhage in drug-induced thrombocytopenia. Chest 1981, 79:358-359.
176. Howrie D.L., Schwinghammer T.L., Wollman M. Use of i.v. immune globulin for treatment of phenytoin-induced thrombocytopenia. Clin Pharm 1989, 8:734-737.
177. Ray J.B., Brereton W.F., Nullet F.R. Intravenous immune globulin for the treatment of presumed quinidine-induced thrombocytopenia. Dicp 1990, 24:693-695.
178. Pourrat O. Treatment of drug-related diseases by plasma exchanges. Ann Med Interne (Paris) 1994, 145:357-360.
179. Herrington A., Mahmood A., Berger R. Treatment options in sulfamethoxazole-trimethoprim-induced thrombocytopenic purpura. South Med J 1994, 87:948-950.